CervoMed Stock
CervoMed Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- John J. Alam
- Employees
- 15
- Market cap
- $34 M
- IPO
- 23/05/2008
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a. Neflamapimod…
CervoMed stock: price history
1D
-0.4%
1W
-30.4%
1M
-8.2%
6M
-43.7%
YTD
-71.6%
1Y
-70.5%
2Y
-84.1%
5Y
-93.8%
10Y
-100.0%
Next earnings date
Next earnings date
12/11/2026 (in 26 days)
Volatility around earnings
~20% stronger price swings than usual
Ask the agents about CervoMed
Analyst assessment of CervoMed
PRICE TARGET LOW
US$7.00
CONSENSUS
US$7.00
MEDIAN
US$7.00
PRICE TARGET HIGH
US$7.00
0
STRONG BUY
7
BUY
0
HOLD
0
SELL
0
STRONG SELL
7
TOTAL · Buy
As of: 05/10/2026
CervoMed stock metrics
P/E
-0.7
P/B
1
EV/EBITDA
-0.38
RETURN ON EQUITY
-28.6%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
63.5%
FLOAT SHARES
9,604,406
AVG. DAILY VOLUME (30D)
266,422
Insider transactions (SEC)
BOGER JOSHUA S
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about CervoMed stock
What does CervoMed do?
CervoMed Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is John J. Alam, the company employs around 15 people.
The IPO was on 23/05/2008; the stock trades on NASDAQ under the ticker CRVO.
What do analysts say about CervoMed stock?
7 analysts rate the stock, the consensus is Buy (as of 05/10/2026).
The average price target is US$7.00, ranging from US$7.00 to US$7.00, with a median of US$7.00.
This is an external assessment, not a statement by Market Jury.
When does CervoMed report next?
The next earnings date is 12/11/2026.
Around past earnings, price swings were roughly 20% stronger than usual.
Does CervoMed pay a dividend?
No, CervoMed currently does not pay a dividend.
Which stocks are comparable to CervoMed?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get CervoMed stock analyzed?
Clicking "Analyze stock" lets five strategies assess CervoMed against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.